Now Reading: Sun Pharma sees Ilumya recovery, Organon on track
-
01
Sun Pharma sees Ilumya recovery, Organon on track
The Story in Brief
Sun Pharmaceutical Industries expects sales of its psoriasis drug Ilumya in the US to improve over the coming months, after the September 2026 quarter faced headwinds from purchasing decisions and pricing pressures. The company is strengthening its dermatology and immunology teams and noted new approvals for psoriatic arthritis as an opportunity to expand reach.
Chief Financial Officer Jayashree Satagopan said the company expects to close the acquisition of Organon by the end of 2026 and will meet earlier FY27 guidance. The company reported Q2 FY27 revenue of ₹16,199 crore, with profit before tax of ₹1,989 crore and margins of 29.3%. India sales grew 17.3% to ₹5,552.3 crore, while US sales fell 8.2% to $455 million.
Indian Opinion Analysis
CNBC-TV18's interview-focused coverage leads with the Ilumya recovery plan and the Organon timeline, presenting the company's own explanations for the slowdown without challenge. Business Today leads with the headline numbers, foregrounding the 11.8% sales growth and the 8.2% US decline, giving a more results-driven account. Both outlets carry the same company guidance on Organon and FY27, so coverage on those points is uniform. The main difference is framing: CNBC-TV18 emphasises management's forward outlook, while Business Today stresses the mixed quarterly performance. Neither outlet probes the pricing pressures or the borrowing cost impact of higher rates, so investors are left with the company's assurance that fixed and floating rate mix will keep costs comparable. Watch the Q3 FY27 numbers, due early next year, for evidence of Ilumya's US recovery.
Watch the company's annual budgeting exercise, which will determine FY28 guidance.
Coverage: 2 sources, 2 neutral
Sources (2): cnbctv18.com (neutral report), businesstoday.in (neutral report)
This brief was synthesised by AI from the 2 sources linked above, so one read covers every framing they carry. Methodology and corrections.
